Transplantation and Cellular Therapy Meetings | Conference

Iomab-B Prior to Allogeneic HCT Improves Durable Complete Remission Rate in Older Patients With R/R AML

February 19th 2023

High initial complete remission with or without platelet recovery, as well as an improvement in durable complete remission was achieved with the use of Iomab-B-based conditioning prior to allogeneic hematopoietic cell transplantation compared with conventional care in older patients with relapsed/refractory acute myeloid leukemia.

Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD

February 19th 2023

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.

Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALL

February 19th 2023

Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.

Ide-Cel Improves PFS and ORR in Triple-Class Exposed, Early R/R Multiple Myeloma

February 19th 2023

Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.

Chronic Opioid Use Following ASCT Linked With Poor Survival Outcomes in Multiple Myeloma

February 18th 2023

Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.

Orca-T Leads to High RFS Rates in Acute Leukemias and MDS

February 18th 2023

Treatment with the cellular therapy Orca-T produced an improved graft-vs-host-disease and relapse-free survival rate in patients with high-risk myelodysplastic syndrome or acute leukemias.

Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma

February 18th 2023

Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.

Dr. Srour on Orca-Q Transplantation in Hematologic Malignancies

February 18th 2023

Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.

Novel Therapies Are Needed to Reduce Cost Burden With AlloHCT, GVHD

February 17th 2023

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

Ruxolitinib Induces High Responses in SR-aGVHD, Regardless of Cytopenias

February 17th 2023

The presence of cytopenias did not affect the favorable and durable responses seen with ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host disease.

Ruxolitinib Provides ORR Benefit vs BAT in Early Treatment of SR-aGVHD

February 17th 2023

Early treatment with ruxolitinib led to high response rates in patients with steroid refractory acute graft-vs-host-disease, although benefits with ruxolitinib vs best available therapy were observed regardless of the timing of ruxolitinib administration.

Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and Under

February 17th 2023

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17th 2023

Orca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encouraging outcomes for patients with high-risk hematologic malignancies.

CD22-Directed CAR T-cell Therapy Elicits High CR Rates in LBCL After CD19 Relapse

February 17th 2023

CD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.

Salvage Checkpoint Inhibitors Reduce Peri-ASCT Progression in R/R Hodgkin Lymphoma

February 17th 2023

Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.

Orca-T Leads to 100% Survival Rate in Early Trial of Patients With Hematologic Malignancies and 7/8 Mismatched Donors

February 17th 2023

Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.

Real-world OS Rates in aGVHD Increase in Ruxolitinib Treatment Era

February 17th 2023

Ruxolitinib induced clinically meaningful overall survival improvements by decreasing non-relapse mortality rates in patients with acute graft-vs-host-disease.

Frontline Itolizumab Elicits Durable Responses in aGVHD

February 17th 2023

First-line treatment with itolizumab produced rapid, durable responses and favorable safety in patients with acute graft-vs-host disease.

Treatment Approaches Should Remain Consistent Across Late and Classic aGVHD

February 17th 2023

Timing of severe symptom onset is the only distinct difference between late and classic acute graft-vs-host disease, and long-term outcomes were similar between the two types of disease.

Ide-Cel Is Effective, Safe for Patients With R/R Multiple Myeloma and Renal Insufficiency

February 17th 2023

Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.